ChemoCentryx Inc (CCXI)

6.26
NASDAQ : Health Care
Prev Close 6.33
Day Low/High 6.13 / 6.40
52 Wk Low/High 1.92 / 9.10
Avg Volume 217.70K
Exchange NASDAQ
Shares Outstanding 47.81M
Market Cap 302.61M
EPS -1.10
P/E Ratio 5.28
Div & Yield N.A. (N.A)

Latest News

ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016

ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016

Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation

ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer

ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer

Company expects additional data including progression-free survival by the end of 2016

First Week of CCXI February 2017 Options Trading

First Week of CCXI February 2017 Options Trading

Investors in ChemoCentryx, Inc. saw new options become available this week, for the February 2017 expiration.

ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis

ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis

PRIME designation designed to provide path to expedite clinical development and accelerate marketing authorization applications

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting

ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting

Psoriasis Treatment via Inhibition of Chemokine Receptor CCR6 Supported by In Vivo Model Data

ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research (AACR) Annual Meeting

ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research (AACR) Annual Meeting

Potentiation of anti-tumor effect observed with combination of small molecule chemokine receptor CCR1 inhibitor and PD-L1 checkpoint inhibitor in triple negative breast cancer model

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade much higher from current levels.